25% w/v DEXTROSE INJECTION USP Infusion
Dextrose 25%
250mg/ml
Qatar Pharma
| Pack size | 50ml Plastic Bag |
|---|---|
| Dispensing mode | POM |
| Source | QATAR |
| Agent | PHARMAWORLD |
| Retail Price | 2.50 AED |
Available as:
Indications
25% w/v DEXTROSE INJECTION USP Infusion is used for:
Parenteral Nutrition and Hydration, Hypoglycemia, Hyperkalaemia, Energy malnutrition
Adult Dose
Intravenous
Hypoglycaemia
Adult: 10-25 g (40-100 ml of 25% solution). Doses may be repeated in severe cases.
Hyperkalaemia
Adult: 25-50 g combined with 10 units of regular insulin, administered over 30-60 minutes; may repeat if necessary.
Alternatively, 25 g combined with 5-10 units of regular insulin infused over 5 minutes; may repeat if necessary.
Child Dose
Intravenous
Hypoglycaemia
Child: <6 mth: 0.25-0.5 g/kg/dose;
>6 mth: 0.5-1 g/kg/dose. Doses may be repeated in severe cases. Max: 25 g/dose.
Hyperkalaemia
Child: and infants: 0.5-1 g/kg (using 25% or 50% solution) combined with regular insulin (1 unit for every 4-5 g dextrose given); infuse over 2 hr, may repeat if necessary.
Renal Dose
Administration
Contra Indications
Known allergy to corn or corn products. Diabetic coma with hyperglycaemia. Use of hypertonic solutions in patients with intracranial or intraspinal haemorrhage. Patients with delirium tremens and dehydration. Anuria, hepatic coma, or glucose-galactose malabsorption syndrome.
Precautions
Overt or known subclinical DM. Patients with carbohydrate intolerance. IV admin of dextrose may result in hypokalaemia, hypophosphataemia and hypomagnesemia. Prolonged infusion of isotonic dextrose solutions may cause water intoxication. Production of insulin may be adversely affected by prolonged parenteral nutrition with dextrose solutions. Rapid admin of hypertonic dextrose solutions may result in hyperglycaemia and hyperosmolar syndrome. Monitor for signs of mental confusion or loss of consciousness. Monitor blood and urinary glucose regularly. Caution when used in very low birth weight infants. Abrupt withdrawal may lead to rebound hypoglycaemia. Risk of thrombosis when hypertonic (>10%) solutions are administered through peripheral veins. Caution when used parenterally in pregnant women.
Lactation: Excretion in milk unknown; use with caution
Pregnancy-Lactation
Pregnancy Category: C
Maternal and fetal hyperglycemia may occur during labor and delivery; monitor
Lactation: Excretion in milk unknown; use with caution
Interactions
Adverse Effects
Side effects of Dextrose 25% :
Venous thrombosis, phlebitis, hypovolemia, hypervolemia, dehydration, oedema, fever, mental confusion, unconsciousness, hyperosmolar syndrome, hyperglycaemia, hypokalaemia, acidosis, hypophosphataemia, hypomagnesemia, polyuria, glycosuria, ketonuria, nausea, diarrhoea, polydipsia, vein irritation, tissue necrosis, pulmonary oedema, tachypnoea.
Mechanism of Action
Dextrose is a monosaccharide that is used as a source of calories and water for hydration. It helps to reduce loss of body protein and nitrogen. It also promotes glycogen deposition in the liver. When used with insulin, it stimulates the uptake of potassium by cells, especially in muscle tissue, thus lowering serum potassium levels.
Note
25% w/v DEXTROSE INJECTION USP 250mg/ml Infusion manufactured by Qatar Pharma. Its generic name is Dextrose 25%. 25% w/v DEXTROSE INJECTION USP is availble in United Arab Emirates.
Farmaco UAE drug index information on 25% w/v DEXTROSE INJECTION USP Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Dextrose 25% :
Infusion
25% w/v DEXTROSE INJECTION USP
250mg/ml
Qatar Pharma
Infusion
25% w/v DEXTROSE INJECTION USP
250mg/ml
Qatar Pharma
Infusion
25% w/v DEXTROSE INJECTION USP
250mg/ml
Qatar Pharma
Infusion
25% w/v DEXTROSE INJECTION USP
250mg/ml
Qatar Pharma
Infusion
25% w/v DEXTROSE INJECTION USP
250mg/ml
Qatar Pharma